Schubert & Co’s Novavax NVAX Stock Holding History

Schubert & Co’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-3	Closed	–	–	1509
2022 Q2	$0	Buy	3 +2	+200%	+$104	﹤0.01%	1548
2022 Q1	$0	Sell	1 -1	-50%	-$89	﹤0.01%	1251
2021 Q4	$0	Buy	+2	New	+$344	﹤0.01%	1197

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Schubert & Co's NVAX Position: Q3 2022 in Review

Schubert & Co sold out of Novavax (NVAX) in Q3 2022, closing a stake of 3 shares.

Schubert & Co first reported a position in NVAX in Q4 2021 and held it in 3 quarters. The position peaked at $0 in Q2 2022. 253 funds tracked by Wall St. Rank hold NVAX as of Q3 2022.

Schubert & Co reported no remaining Novavax position as of Q3 2022 after selling out during the quarter.
Schubert & Co sold 3 Novavax shares in Q3 2022.
Schubert & Co first reported a position in Novavax in Q4 2021 and held it in 3 quarters.
Schubert & Co's Novavax position peaked at $0 in Q2 2022.
253 funds tracked by Wall St. Rank held Novavax as of Q3 2022.

Based on Schubert & Co's 13F filing for Q3 2022, filed 21 Oct 2022.